Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Mesoblast.
RELATED STOCKHEAD STORIES
Health & Biotech
How many stocks fighting COVID-19 have maintained their momentum?
Experts
Scopo’s health powerplays: The cash caboose keeps rolling on
News
Kick Back: The 10 biggest stories you might have missed on Stockhead this week
News
Bell Financial flags improved $23.5m H1 profit but shares dip
Health & Biotech
Dr Boreham’s Crucible: Mesoblast within months of 3 major trial results, key regulatory decision
Health & Biotech
COVID-19 adds $9bn to top four ASX health stocks
News
ASX rainmakers more than double their raisings in 2020 to $27bn
Experts
Scopo’s health powerplays: Clinical trials are back
Health & Biotech
We’re still here: investors keen on health despite market shun
Health & Biotech
COVID-19 treatments are a better bet than a vaccine
Experts
